p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study is a dataset published in The Journal of Pathology Clinical Research (2023). On theSindex it has a DataRank of 0.751, placing it in the top 26.8% of the data-sharing corpus. It has been cited 28 times, with 14 citing works in its 1-hop citation network. Its calibrated FAIR score is 4/100.
Ranks in the top 27% for downstream scientific impact
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
Full FAIR picture · advisory
The headline score is computed from the scored criteria — the fact-shaped checks (a repository, an accession, a licence) that two independent models agree on. The advisory criteria below are real FAIR guidance but rest on judgment calls that models read differently, so they inform without moving the number.
No persistent identifier (DOI, Handle, accession) is given for the data.
RDA-F1-01D — FAIR Data Maturity Model: 'Data is identified by a persistent identifier' (priorit · RDA-F1-02D — FAIR Data Maturity Model: 'Data is identified by a globally unique identifier' · FsF-F1-02D — F-UJI/FAIRsFAIR: 'Data is assigned a persistent identifier'
No repository is named as holder of the data.
RDA-F4-01M — FAIR Data Maturity Model: metadata is offered so it can be harvested and indexed ( · NIH DMS Policy Element 4 (NOT-OD-21-014) — name the repository where data will be archived · NSTC Desirable Characteristics of Data Repositories (2022) — 'Long-Term Sustainability', 'Reten
No identifier for the dataset appears anywhere.
FORCE11 Joint Declaration of Data Citation Principles (2014) — data should be cited as a first- · RDA-F3-01M — metadata clearly and explicitly includes the identifier of the data it describes · FsF-F3-01M — F-UJI: 'Metadata includes the identifier of the data it describes'
Advisory · not in the published score
“Individual patient data and related tumor information underlying this article cannot be shared publicly due to data privacy protection laws. However, grouped data will be shared on reasonable request to the corresponding author.”
The statement points to a person (Colavizza category 1).
Colavizza, Hrynaszkiewicz, Staden, Whitaker & McGillivray (2020), 'The citation advantage of li · Springer Nature research data policy — Data Availability Statements: standard statement templat · RDA-F3-01M — metadata clearly and explicitly includes the identifier of the data it describes
“The analysis included 6,678 patients with one of the three most common ovarian carcinoma histotypes (HGSC, EC, and CCC).”
The dataset's extent is stated in running prose, but no itemised inventory (section, table, or list) of files or variables is provided. [majority verdict 'partial' (3/5 passes agreed)]
RDA-F2-01M — 'Rich metadata is provided to allow discovery' (priority Essential) · FsF-F2-01M — F-UJI: 'Metadata includes descriptive core elements to support data findability' · FsF-R1-01MD — F-UJI: 'Metadata specifies the content of the data'
“Individual patient data and related tumor information underlying this article cannot be shared publicly due to data privacy protection laws. However, grouped data will be shared on reasonable request to the corresponding author.”
The only route is a discretionary request to a person, not a followable process.
RDA-A1.1-01D — 'Data is accessible through a free access protocol' · FsF-A1-01M — F-UJI: 'Metadata contains access level and access conditions of the data' · NSTC Desirable Characteristics of Data Repositories (2022) — 'Free and Easy Access'
Advisory · not in the published score
“grouped data will be shared on reasonable request to the corresponding author.”
The paper does not label the access level; it only describes an action (request). [majority verdict 'no' (3/5 passes agreed)]
FsF-A1-01M — F-UJI: 'Metadata contains access level and access conditions of the data' · RDA-A1-01M — metadata contains information to enable the user to get access to the data · COAR Controlled Vocabularies — Access Rights v1.0 (open / embargoed / restricted / metadata-onl
“grouped data will be shared on reasonable request to the corresponding author.”
The gatekeeper is a natural person (the corresponding author).
NIH Genomic Data Sharing Policy (NOT-OD-14-124) — controlled-access via a Data Access Committee · RDA-A1.2-01D — 'Data is accessible through an access protocol that supports authentication and · NIH DMS Policy Element 5 (NOT-OD-21-014) — Access, Distribution, or Reuse Considerations (conse
No statement about timing or persistence of data availability.
NIH DMS Plan Element 4 (NOT-OD-21-014) — Data Preservation, Access, and Associated Timelines · NSTC Desirable Characteristics (2022), Organizational Infrastructure: 'Retention Policy' · RDA-A2-01M — 'Metadata is guaranteed to remain available after data is no longer available'
No file format is named for the released data.
FsF-R1.3-02D — F-UJI: 'Data is available in a file format recommended by the target research co · RDA-R1.3-02D — data is expressed in a machine-understandable community standard · RDA-I1-01D — data uses a knowledge representation expressed in a standardised format
Advisory · not in the published score
No data/metadata community standard is named; only WHO classification (not a data standard) is used. [majority verdict 'no' (4/5 passes agreed)]
RDA-R1.3-01M — 'Metadata complies with a community standard' (priority Essential) · RDA-R1.3-01D — 'Data complies with a community standard' · RDA-I2-01M — '(Meta)data use vocabularies that follow FAIR principles'
No identifiers for external resources used (only citations).
RDA-I3-01M — '(meta)data include references to other (meta)data' · RDA-I3-03M — 'metadata includes qualified references to other metadata' · FsF-I3-01M — F-UJI: 'Metadata includes links between the data and its related entities'
No licence is named for the data; the article's CC BY licence does not apply to the data.
RDA-R1.1-01M — 'Metadata includes information about the licence under which the data can be reu · RDA-R1.1-02M — 'Metadata refers to a standard reuse licence' · RDA-R1.1-03M — 'Metadata refers to a machine-understandable reuse licence'
No version token or date for the data.
DataCite Metadata Schema 4.6 — the 'Version' property · RDA-R1.2-01M — provenance information (which version was used is provenance) · NSTC Desirable Characteristics of Data Repositories (2022) — 'Provenance', 'Retention Policy'
No code availability statement or locator is provided.
NIH DMS Policy Element 2 (NOT-OD-21-014) — 'Related Tools, Software and/or Code' · FAIR4RS Principles v1.0 (Chue Hong et al., 2022; RDA/FORCE11/ReSA) — FAIR Principles for Resear · FORCE11 Software Citation Principles (Smith, Katz & Niemeyer, 2016, PeerJ CS 2:e86)
“The study was funded by Alberta Precision Laboratory research support fund (RS17-601, RS19-609, RS10-526).”
Award numbers are given for the funding.
DataCite Metadata Schema 4.6 — 'FundingReference' property (funderName, funderIdentifier, award · Crossref Funder Registry — canonical funder identifiers for funding metadata · RDA-F2-01M — rich metadata provided to allow discovery (funding is part of the descriptive reco
Advisory · not in the published score
“The first assay (pre-treatment with BOND Epitope Retrieval Solution 2, Leica Biosystems, Wetzlar, Germany; p53 antibody clone DO-7, dilution 1:2,500, Dako Omnis, Agilent, Santa Clara, CA, USA) was used to stain 55.4% of cases and 44.6% of cases were stained with a second assay (pre-treatment for 30 min using heat-induced antigen retrieval with Tris-EDTA buffer, pH = 9.0; ready-to-use antibody DO-7, Dako Omnis) due to a change in the automated IHC platform during the study period.”— not found in the paper; verdict downgraded
The paper names specific instruments, kits, and antibodies used. [downgraded to 'partial' — no verifiable quote from the paper] [majority verdict 'partial' (4/5 passes agreed)]
RDA-R1.2-01M — 'Metadata includes provenance information according to community- specific standa · FsF-R1.2-01M — F-UJI: 'Metadata includes provenance information about data creation or generati · W3C PROV-O (W3C Recommendation, 2013) — the entity/activity/agent model of provenance
“Table 1. Clinicopathological characteristics and p53 expression patterns across histotypes”
Variable definitions are given inside the article in Table 1, not in a separate documentation object shipped with the data [majority verdict 'partial' (3/5 passes agreed)]
RDA-R1-01M — '(Meta)data are richly described with a plurality of accurate and relevant attribu · FsF-R1-01MD — F-UJI: 'Metadata specifies the content of the data' · NIH DMS Policy Element 3 (NOT-OD-21-014) — Standards (documentation and metadata to accompany t
Calibrated FAIR score — a parallel quality metric, independent of the DataRank citation score. See the full evaluation →
Base Score Contribution
0.505
From this paper's citation signal
Citation Network Contribution
0.246
From 10 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 14 citers.
Medical Research and Materiel Command
Grant: DAMD17‐01‐1‐0729
National Health and Medical Research Council
Grant: 628903
Australasian Biospecimen Network - Oncology
National Health and Medical Research Council
Grant: 310670
Australasian Biospecimen Network-Oncology
National Health and Medical Research Council
Grant: ID400281
National Health and Medical Research Council
Grant: ID400413
National Health and Medical Research Council
Grant: ID199600
National Health and Medical Research Council
Grant: APP2009840
National Health and Medical Research Council
Grant: 15/RIG/1‐16
National Health and Medical Research Council
Grant: 12/RIG/1‐17
Cancer Research Society
Grant: 19319
Instituto de Salud Carlos III
Grant: PI 12/01319
Ministerio de Economía y Competitividad
Grant: SAF2012
National Institutes of Health
Grant: U01‐CA69417
National Institutes of Health
Grant: U01‐CA71966
National Institutes of Health
Grant: N01‐PC‐67001
National Institutes of Health
Grant: N01‐CN‐55424
National Institutes of Health
Grant: R01‐CA58598
U.S. Department of Defense
Grant: DAMD17‐02‐1‐0669
American Cancer Society
Grant: SIOP‐06‐258‐01‐COUN
National Center for Advancing Translational Sciences
Grant: UL1TR000124
National Institutes of Health
Grant: P50‐CA136393
National Institutes of Health
Grant: P30‐CA15083
National Institutes of Health
Grant: R01‐CA243483
National Institutes of Health
Grant: R01‐CA122443
Cancer Research UK
Grant: C490/A16561
Swedish Cancer Foundation
Grant: CAN 2018/384
Canadian Institutes of Health Research
Grant: MOP‐86727
NIHR Cambridge Biomedical Research Centre
Grant: BRC‐1215‐20014
NCI NIH HHS
Grant: P30 CA047904
NCI NIH HHS
Grant: P50 CA136393
Cancer Research UK
Grant: 15601
Medical Research Council
Grant: MC_UU_00004/01
Evaluating new healthcare technologies in cancer
NCI NIH HHS
Grant: R01 CA248288
Cancer Research UK
Grant: 22905
NCI NIH HHS
Grant: P30 CA015083
NCI NIH HHS
Grant: R01 CA058598
NCI NIH HHS
Grant: R01 CA095023
NCI NIH HHS
Grant: R01 CA122443
NCI NIH HHS
Grant: U01 CA069417
NCI NIH HHS
Grant: R01 CA168758
NCRR NIH HHS
Grant: M01 RR000056
NCI NIH HHS
Grant: N01 CA015083
NIH HHS
Grant: P30-CA15083
NIH HHS
Grant: P50-CA136393
NCI NIH HHS
Grant: R01 CA112523
NCI NIH HHS
Grant: P30 CA071789
NCI NIH HHS
Grant: R01 CA087538
NCI NIH HHS
Grant: R01 CA160669
NIH HHS
Grant: R01-CA243483
NCATS NIH HHS
Grant: UL1 TR001881
NCI NIH HHS
Grant: K07 CA080668
NIH HHS
Grant: R01-CA122443
NCI NIH HHS
Grant: U01 CA243483
NCI NIH HHS
Grant: R01 CA243483
National Health and Medical Research Council (NHMRC)
Grant: 400413
Australian Ovarian Cancer Study (AOCS): A multidisciplinary ovarian cancer resource for the genomic era
National Institutes of Health
Grant: 5R01CA112523-03
Steroid Hormone Genes and Ovarian Cancer Risk
National Institutes of Health
Grant: 5R01CA087538-02
Epidemiology of Ovarian Cancer:New Hypotheses
Canadian Institutes of Health Research
Grant: unidentified
unidentified
National Health and Medical Research Council (NHMRC)
Grant: 400281
Molecular Epidemiology of Ovarian Cancer: The Australian Ovarian Cancer Study National Clinical Follow-Up Core
National Institutes of Health
Grant: 5P50CA136393-10
Mayo Clinic Ovarian Cancer SPORE
National Institutes of Health
Grant: 5R01CA160669-02
Mitochondrial DNA and Ovarian Cancer Risk and Survival
National Institutes of Health
Grant: 5U01CA071966-02
GENETIC EPIDEMIOLOGY OF OVARIAN CANCER
National Institutes of Health
Grant: N01PC067001-001
SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS PROGRAM
National Institutes of Health
Grant: 5R01CA122443-06
Genetic Variation in the NF-kappaB Pathway and Ovarian Cancer Etiology
National Institutes of Health
Grant: N01CN055424-007
SURVEILLANCE EPIDEMIOLOGY AND END RESULTS (SEER)
National Institutes of Health
Grant: 5U01CA069417-02
NORTHERN CALIFORNIA COOPERATIVE FAMILY REGISTRY
National Institutes of Health
Grant: 5R01CA243483-04
Sequencing Familial Lung Cancer
National Institutes of Health
Grant: 5R01CA095023-03
Inflammation and Ovarian Cancer
National Institutes of Health
Grant: 5UL1TR000124-04
UCLA Clinical and Translational Science Institute
National Institutes of Health
Grant: 3P30CA047904-07S1
CANCER CENTER SUPPORT GRANT
National Institutes of Health
Grant: 3P30CA015083-37S2
Mayo Comprehensive Cancer Center Grant
National Health and Medical Research Council (NHMRC)
Grant: 199600
Towards cancer control: Population and molecular strategies
National Institutes of Health
Grant: 5K07CA080668-06
OVARIAN CANCER RISK AND SURVIVAL IN BRCA CARRIERS
National Institutes of Health
Grant: 4R01CA168758-04
Epidemiologic factors and survival by molecular subtypes of ovarian cancer
National Institutes of Health
Grant: 5R01CA058598-05
COLLABORATIVE STUDY OF OVARIAN CANCER IN TWO RISK GROUPS
Biomedical Research Centre
European Regional Development Fund
Mayo Foundation for Medical Education and Research
National Institute for Health Research (NIHR)
Pomorski Uniwersytet Medyczny W Szczecinie
Cancer Council NSW
Cancer Institute NSW
Deutsches Krebsforschungszentrum
University College London Hospitals Biomedical Research Centre
Breast Cancer Now
Cancer Council Tasmania
Ovarian Cancer Australia
Fred C. and Katherine B. Andersen Foundation
Institute of Cancer Research
Minnesota Ovarian Cancer Alliance
Peter MacCallum Foundation
University of Cambridge
VGH and UBC Hospital Foundation
Cancer Council Victoria
Cancer Council South Australia
Oak Foundation
Sydney West Translational Cancer Research Centre
Department of Health
Breast Cancer Now
FWCI
5.75
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals